

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	LAUTT ET AL.	Examiner:	S. JAVANMARD
Serial No.:	10/502,119	Group Art Unit:	1617
Filed:	JANUARY 12, 2005	Docket No.:	14430.6USWO
Confirmation No.:	3382	Customer No.:	23552
Title:	USE OF PHOSPHODIESTERASE ANTAGONISTS TO TREAT INSULIN RESISTANCE		

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

This paper is being submitted in response to the Restriction Requirement mailed January 3, 2008. Without acquiescing to the statements made therein, Applicants hereby elect the claims of Group III (claims 22, 48, 50, 52, 54, 56, 58, 60, 62 and 64) for prosecution in the instant application. In addition, the Examiner has required an election of a species. To fulfill the election of species requirement, Applicants elect tadalafil as the phosphodiesterase antagonist.


Applicants reserve the right to file one or more divisional applications on non-elected subject matter.

Examination on the merits is respectfully requested.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: 1/31/2008



Brian R. Dorn, Ph.D.
Reg. No. 57,395

23552

PATENT TRADEMARK OFFICE